GSK plc (GSK.L) Friday said that the European Medicines Agency (EMA) has accepted the company's application to expand the use of its RSV vaccine, Arexvy to include individuals aged 18 years and older
A decision from the regulator is expected in the first half of 2026.
Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older. It is also approved for adults aged 50-59 who are at increased risk for RSV disease.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.